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ABSTRACT
Purpose The purpose of this study was to determine the im-
pact of food on gastric pH and the ability of over the counter
betaine hydrochloride (BHCl) acid to reacidify gastric pH af-
ter food-induced elevations in gastric pH.
Methods This open-label cross over clinical study
(NCT02758015) included 9 subjects who were randomly
assigned to one of 16 possible, 4-period cross-over sequences
to determine the impact and relationship of food and gastric
pH with acid supplementation. Subjects were administered
various doses (1500 mg, 3000 mg and 4500 mg) of betaine
hydrochloride (BHCl) to determine the ability of acid supple-
mentation to reacidify gastric pH after the elevation of gastric
pH caused by the ingestion of food.
Results Following the administration of food and the
resulting elevation in gastric pH, time to return to baseline
gastric pH levels without acid supplementation was 49.7 ±
14.0 min. Administering 4500 mg of BHCl acid in capsules
was able to reacidify gastric pH levels back to baseline follow-
ing the administration of food in approximately 17.3 ±
5.9 min. AUCpH of each treatment were similar and not sta-
tistically different. Meanmax pH following the administration
of food was 3.20 ± 0.55.
Conclusion The ability of food to elevate and maintain gas-
tric pH levels in the presence of acid supplementation was
made evident throughout the study. A 4500 mg dose of
BHCl was required to reacidify gastric pH after the adminis-
tration of food. This study details the difficulty faced by clini-
cians in dosing a poorly soluble, weakly basic drug to patients
receiving acid reducing agents where administration with food
is recommended to avoid gastric side effects.
Trial Registration: https://clinicaltrials.gov/ct2/show/
NCT02758015
KEY WORDS betaine hydrochloride . gastric pH . gastric
reacidification . meal effects
ABBREVIATIONS
ARA Acid reducing agent
BHCl Betaine hydrochloride
GERD Gastroesophageal reflux disease
PPI Proton pump inhibitor
INTRODUCTION
The impact of drug solubility and dissolution is important when
considering the absorption of orally administered drugs.
Absorption is influenced by both a combination of physicochem-
ical properties of the drugs in question [distribution-coefficient or
partition coefficient (log P), native ionic state, and acid dissocia-
tion constant (pKa)] and also physiological factors of the gastro-
intestinal tract (1–3). Gastric pH, a physiological factor, plays an
essential role in determining the appropriate physiological pa-
rameters facilitating solubility and absorption (3). The ability of
varying levels of gastric pH to have an effect on drug absorption
and systemic bioavailability has been well investigated previously
(1,3–8). Weakly basic drugs that have a pH-dependent solubility
profile and are orally administered are most vulnerable to vary-
ing gastric pH levels. When the gastric pH levels rise above the
pKa of weakly basic drugs then pH-based interactions,
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particularly regarding drug-solubility, are emphasized. These
pH-based interactions can have clinically meaningful implica-
tions resulting in toxicity or reduced therapeutic efficacy.
Gastric pH levels are often elevated by commonly prescribed
medications, acid-reducing agents (ARAs), which are generally
prescribed for gastrointestinal diseases. According to a report,
The Burden of Digestive Diseases in the United States, released by the
National Institute of Health (NIH) in 2008 (9), there were over
60-million annual prescriptions filled at pharmacies in theUnited
States in 2004 for the treatment of gastroesophageal reflux dis-
ease (GERD). Proton pump inhibitors (PPIs), such as omeprazole
andH2-receptor antagonists (H2-RAs), such as ranitidine, are the
most common classes of ARAs used for GERD. Furthermore, it
has been estimated that in the United States PPI’s have been the
preferred treatment for greater than 50% of digestive disorders,
which amounts to more than $11 billion dollars annually (10)
and results in ARAs being themost widely prescribedmedication
in North America (11). The risk of polypharmacy is abundant
and it is important for the medical community to address and
mitigate these risks.
Prior data in 2013 by Yago et al. successfully demonstrated
the ability of betaine hydrochloride (BHCl) to transiently and
rapidly re-acidify gastric pH in healthy volunteers pretreated
with rabeprazole to induce hypochlorhydria (1). BHCl is an
over the counter (OTC) nutraceutical that is used as a diges-
tive aid, and has clinical efficacy in homocystinuria (1). With a
pKa of 1.83 (12), BHCl dissociates to a large extent to give
zwitterionic betaine, protons and chloride ions, with virtually
complete dissociation being observed up to millimolar BHCl
concentration levels in water (12), thus acidifying gastric fluid.
BHCl was observed to rapidly and temporarily increase gas-
tric acidity in subjects with drug-induced hypochlorhydria
(pH >4) (1). The mean onset of reacidification (pH <3) was
approximately 6.3 min and the decrease in pH was transient,
with pH< 3 lasting for only about 73 min. These findings led
to a successful follow-up study demonstrating the ability of a
single dose of 1500 mg of BHCl to fully restore the lost Cmax
and AUC0-∞ of dasatinib in healthy fasting volunteers after
dosing with rabeprazole (5).
Based on findings from that study, the utilization of BHCl
was explored, to regain lost bioavailability of atazanavir
(ATV) in healthy volunteers pretreated with rabeprazole un-
der fed conditions (6). In that study, Faber et al. demonstrated
statistically significant reductions in Cmax and AUC of ATV
when healthy subjects were pretreated with rabeprazole, as
was expected. However, the administration of 1500 mg
BHCl under fed conditions in healthy volunteers only restored
13% and 12% of ATV Cmax and AUC, respectively. These
increases were not statistically significant. We noted that the
inability to recover lost bioavailability due to rabeprazole-
induced achlorhydria was multi-factorial. One reason being
that ATV was dosed with ritonavir (RTV), a cytochrome
P450 enzyme inhibitor that serves to boost or increase serum
concentrations of ATV by preventing its metabolism. RTV is
also affected by gastric pH changes and we postulated that
ATV was not appropriately boosted due to the decrease in
RTV bioavailability. Another factor further complicating this
study was the administration of food prior to ATV and RTV
dosing. This was done to replicate clinical settings in which
food is recommended in the label to be administered with
ATV and RTV to decrease GI toxicity. Based on a review
of previous data from the Benet Lab (1,5,6), increases in gas-
tric pH when fasting subjects were not taking concomitant
ARAs and are fed were observed. Gastric pH levels rise from
baseline values between 0.5 and 1 and increase to a pH pla-
teau between 2 and 3. Conversely, when fasting subjects are
fed a standardized meal in the presence of ARA induced
achlorhydria (baseline pH> 4), their pH decreases and pla-
teaus at a pH between 2 and 3. These observations demon-
strate the complexity of the gastric pH effect of food. The dose
of BHCl used in Faber et al.’s study (1500 mg) was unable to
overcome the gastric effects of a meal and reacidify gastric pH
in the setting of ARA induced achlorhydria. The appropriate
dose of BHCl to overcome this gastric pH-food effect is of
interest and could be clinically significant information for the
medical community in dosing basic drugs in GERD patients.
The aim of the study was to characterize the effect of a
standardized meal on fasting stomach pH as well as the time
course and potency of increasing doses (1500 mg, 3000 mg,
4500 mg) of betaine hydrochloride on gastric acidity in fed
healthy volunteers. The hypotheses were that the higher doses
of BHCl would result in a faster time to baseline pH after the
administration of food and that the AUCpH would decrease
proportionally as the dose of BHCl was increased. The pri-
mary outcome variable is time to baseline gastric pH after the
administration of BHCl. Secondary outcomes included
AUCpH, max pH, and the effect of food on gastric pH.
MATERIALS AND METHODS
We aimed to recruit non-smoking, healthy volunteers between
the ages of 18–64 (per protocol), who were not taking con-
comitant medications (National Clinical Trials ID:
#NCT02758015). The Committee on Human Research of
the University of California, San Francisco (UCSF), approved
this study on 08/29/2016 and the research was conducted at
the UCSF Clinical Research Center. Recruitment was con-
ducted using fliers around the campus, and telephone pre-
screen interviews were conducted for interested subjects.
Once deemed eligible via telephone screening and after pro-
viding written informed consent, patients’ eligibility for the
study was determined during an in-person screening visit.
The 2-h screening visit consisted of routine laboratory value
measurements (complete blood count, complete metabolic
panel), medical history review, physical examination and
155 Page 2 of 10 Pharm Res (2019) 36: 155
baseline gastric pH measurement using the Heidelberg pH
Diagnostic System (Heidelberg Medical, Inc., Mineral Bluff,
GA) to confirm normochlorhydria (fasting gastric pH <4).
As previously described by Yago et al. (1), this FDA approved
radiotelemetry system utilizes a small Heidelberg capsule that is
indigestible. The Heidelberg pH Diagnostic system is a micro-
electric transmitter device designed specifically for inter-
abdominal pHmonitoring and consists of a miniature pH elec-
trode and battery-operated transmitter encapsulated within a
sealed polyacrylate (plastic) capsule, 7 mm in diameter and
15 mm long. This capsule is tethered to a thin, surgical string
that has been pre-measured to allow the capsule to sit in the
stomach when swallowed. Upon swallowing and proper place-
ment, the string was taped to the patient’s cheek to ensure the
capsule did not continue through the gastrointestinal tract. The
pH information from the capsule was transmitted to a trans-
ceiver that interfaces with a PC computer to capture pH data at
1-s intervals. The pH capsule and Heidelberg System are not
radioactive and are specifically designed to safely monitor
intragastric and intraesophageal pH. Subjects who were able
to tolerate the screening procedure and did not have achlor-
hydria (pH> 2) were eligible for the study. Subjects were not
eligible if they had any past medical history of or current gas-
trointestinal diseases, concomitant medication use, ingestion of
grapefruit juice within 7 d of the study days, pertinent allergies,
or gastrointestinal intolerances (e.g., lactose intolerance). No
subjects experienced adverse effects using the Heidelberg
System or the BHCl capsules during any phase of the clinical
study. The BHCl capsules are made from Hypromellose
resulting in solubility that is independent of pH (13).
This study was a randomized prospective, open-label, four
period crossover repeated measures clinical study in which sub-
jects were randomized into one of four periods using Latin
square randomization. The four periods were as follows: 1)
standardized meal only, 2) standardized meal +1500 mg
BHCl, 3) standardized meal +3000 mg BHCl and 4) standard-
izedmeal +4500mgBHCl. Theminimumwashout period was
48 h between subject visits based on previous literature (1,5).
The BHCl was administered with 250 ml of water. Subjects
entered each period fasting for at least 8 h. On each study day,
regardless of the period, baseline gastric pH levels were mea-
sured for 15 min. After baseline measurements, each subject
was given a standard breakfast meal, containing a total of
310 cal. The meal consisted of one 160-cal standard peach
flavored yogurt (1.5 g of fat, 32 g carbohydrates, and 6 g of
protein) and a 150-cal breakfast egg and cheese sandwich (8 g of
fat, 12 g carbohydrates, and 8 g of protein). These foods were
chosen to standardize a typical light breakfast meal that
consisted of about 45%–65% of calories from carbohydrates,
20%–35% from fat and 10%–35% fromprotein (14). This food
composition was similar to the meals used in the prior study by
Faber et al. Each subject had 15 min to finish the food, and at
the 15-min mark, the subjects were given the BHCl.
Based on prior studies, we noted a large effect size with a
mean change in gastric pH of 4.2 with a standard deviation of
0.3 after the administration of betaine hydrochloride in
healthy volunteers (N= 6) pre-treated with multiple doses of
rabeprazole (1). We calculated that a sample size of 8 would
have a power of 0.8 to demonstrate a significant effect. We
assumed we might have up to a 20% drop out rate; therefore,
we aimed to recruit 10 healthy volunteers for the study.
The Heidelberg machine occasionally would send an erro-
neous data point to the computer system. These were deter-
mined by visually observing one-data point that would jump
up several pH points in a given second and back to baseline
the next second. These erroneous pH values were cleaned up
using RVersion 3.6.1. During data-clean up, individual’s data
were sectioned off into different segments: baseline, food ad-
ministration, and BHCl administration. In the baseline por-
tion, any data values that jumped from patient’s baseline by
more than several pH points in a given second were eliminat-
ed. For example, if pH readings are consistently measured
between 0.5–1.5 in the baseline phase, any reading that
jumped to greater than pH 3 in 1 s were determined to be
erroneous. If the pH level jumped in either direction, but was
maintained there, then these values were not eliminated in the
data-clean up phase. This type of cleaning was applied to each
section of an individual’s data. As previously discussed, medi-
an pH intervals for every minute were chosen for the analysis
based on previous literature and thus 1-s erroneous data did
not significantly impact the analyses.
Gastric pH data were collected at 1-s intervals by the
Heidelberg system for the duration of each study visit, which
was 3–4 h. After the administration of BHCl, subjects were
monitored for a total of 3 h. However, based on an interim
analysis, the protocol was later amended to 2 h of monitoring
after the administration of BHCl providing ample time for
gastric pH to return to baseline. Given the vast amount of
gastric pH data attained every second for each subject from
each visit, the median pH data at 1-min intervals were used
for analyses. It has been previously shown that 1-min intervals
can sufficiently depict the pH-time profile (1,15) The calcula-
tion of time to baseline was determined from the time of ad-
ministration of BHCl until the gastric-pH had reached the
baseline levels; in the food only arm the time began at the
administration of food (comparison 1). A separate time to
baseline calculation (comparison 2) was performed with the
starting time point being 15-min after the administration of
food, specifically in the food-only arm. This allowed for a
consistent measure of time to baseline across all treatment
arms since in the BHCl arms, the BHCl was administered
15-min after the administration of food. Baseline gastric pH
levels were determined from gastric-pH measurements col-
lected by the Heidelberg machine during the beginning of
each study visit for each volunteer. Areas under the pH versus
time curves (AUCpH) were calculated using the linear
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Trapezoidal Rule, beginning with the administration of food
until baseline gastric pH levels were reached. The administra-
tion of food was chosen as the starting point for AUCpH to
keep consistency among treatment arms.
A repeated measures analysis of variance (ANOVA) with
Tukey’s test for multiple comparisons was used to determine
statistical significance across all treatments. Geometric mean
ratios and 90% confidence intervals were calculated for
between-group treatment comparisons. Each subject was ran-
domized to receive a standardized meal and 3 varying doses of
BHCl. We measured the time to baseline gastric pH prior to
and after the administration of a BHCl dose in the presence of
a standardized meal, which resulted in elevated pH levels.
The null hypothesis is that there is no difference in the time
to baseline gastric pH with increasing doses of betaine hydro-
chloride compared to the control (standardized meal only and
no betaine hydrochloride). The level of significance was set at
0.05 (alpha). Statistical calculations and descriptive analyses
were done using Sigmaplot 12.5 (Systat Software, San Jose
CA) and GraphPad Prism 8.2.0 (La Jolla, Ca). We also calcu-
lated the AUCpH using the linear trapezoidal method as a
secondary outcome to determine if there is a significant differ-
ence between groups. The null hypothesis for this outcome is
that there is no difference in the AUCpH between the groups.
RESULTS
We enrolled nine healthy, non-smoking volunteers be-
tween the ages of 18 and 64. The protocol was ap-
proved by the University of California San Francisco
Institutional Review Board, and all subjects signed the
approved consent. Subject demographics are summa-
rized in Table I. The breakdown of males and females
Table I Subject
Demographics Total N 9
Sex
Male 4
Female 5
Race/Ethnicity
White 5
Asian 3
Black 1
Baseline pH of All Subjects
Mean 0.75
Range 0.5–2.1
Age (years)
Mean ± SD 40 ± 13
Range 21–59
Fig. 1 The gastric pH vs time plot
for a sample patient from each
treatment arm: food only, 1500 mg
of BHCl, 3000 mg of BHCl and
4500 mg of BHCl.
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was uniform, and the age range for subjects was 21–
59 years old. The mean baseline pH across all nine
volunteers was 0.75. Ethnicity, established by self-
reporting, not obtained by genetic analysis, was collect-
ed as a means of gathering baseline demographics.
Fig. 1 illustrates a representative pH study profile along
with the markings demonstrating the administration of
food, BHCl and baseline levels.
Time to Baseline
There were two comparisons made for the time to baseline
outcome, comparison 1 (beginning when food was adminis-
tered) and comparison 2 (beginning 15 min following food
administration equivalent to when BHCl was administered).
The primary outcome of mean time to baseline after food
administration is shown for comparison 1 in Fig. 2a (Mean
Time to Baseline) and for comparison 2 in Fig. 3a (Mean
Time to Baseline).
When individually comparing pairwise differences in
mean time to baseline between treatment groups and
the control group (Table II), all BHCl treatment arms
compared to the food-only control arm showed a statis-
tically significant decreases in the time to baseline pH.
When comparing the BHCl treatment groups to one
another, the higher doses of BHCl showed statistically
significant decrease in time to baseline to lower doses of
BHCl except for the 1500 mg arm compared to the
3000 mg arm where the difference was insignificant
(P = 0.810, CI [−7.20 to 3.64]). The geometric mean
ratios are consistent with these results as well. The dif-
ference in means of the time to baseline, the p values,
the 90% CI of the difference in means, and the geo-
metric mean ratios are given in Table II.
For the second comparison (comparison 2), the starting
time point in the food-only control arm began 15-min after
the administration of food (Fig. 3). When individually com-
paring pairwise differences in time to baseline between treat-
ment periods and the control group (Table III), the 4500 mg
BHCl treatment arm was statistically significant when com-
pared to the control arm, the 1500 mg BHCl arm and the
3000 mg BHCl arm. All other comparisons between in the
difference in mean time to baseline between the treatment
groups were statistically insignificant (Table III).
Fig. 2 Figure 2a depicts the mean time to baseline for comparison 1 with the
standard deviations shown as error bars. The calculation of time to baseline
was determined from the time of administration of BHCl until the gastric-pH
had reached the baseline levels. In the food only arm of comparison 1, the
time began at the administration of food. Figure 2b illustrates the difference
between group means with 90% confidence interval error bars.
Fig. 3 Figure 3a depicts the mean time to baseline for comparison 2 with the
standard deviations shown as error bars. The calculation of time to baseline
was determined from the time of administration of BHCl until the gastric-pH
had reached the baseline levels. In the food only arm of comparison 2, the
starting time point was 15-min after the administration of food. Figure 3b
illustrates the difference between group means with 90% confidence interval
error bars.
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Mean Max pH
The mean max pH was measured to determine if there was a
significant difference in post-prandial pH among the treat-
ment arms (Table IV). The results demonstrated no difference
between the groups, ensuring that each arm had similar gas-
tric pH effects resulting from the administration of a standard-
ized meal.
Area under the Curve, pH
The area under the curve was assessed to determine the im-
pact on the pH vs. time curve of varying doses of betaine
hydrochloride. The AUCpH was relatively stable regardless
of the dose of BHCl administered. The differences in the
mean values among the treatment groups are not great
enough to exclude the possibility that the differences are due
to random sampling variability; there is not a statistically sig-
nificant difference (P = 0.990). The data are presented in
Table V.
DISCUSSION
These study results demonstrate the powerful effect of food on
elevating and maintaining increased gastric pH and the im-
pact of BHCl in overcoming this pH effect. The ability of food
to elevate gastric pH and maintain elevated pH levels in the
presence of BHCl is much more powerful than what was pre-
viously seen in drug-induced achlorhydria using ARAs. In the
latter study, administration of BHCl was able to quickly and
transiently decrease pH. In this study, there were two major
comparisons. In the first comparison, there was a statistical
difference between each of the BHCl arms compared to the
food-only control arm in decreasing gastric pH. All but one
(1500 mg vs. 3000 mg) of the treatment arms showed a statis-
tically significant difference when compared to one another in
their difference in mean time to baseline. These lower doses
were likely not high enough to counter the strong gastric buff-
ering effect of food. The null hypothesis was that there would
be no difference in doses of BHCl dosing in time to baseline.
We rejected the null hypothesis as the 4500 mg BHCl dosing
reached baseline significantly faster than the other doses,
reaching baseline at 17.3 min. There was no correlation or
significance between the AUCpH and the dose of BHCl. After
administration of BHCl, the data showed fluctuations in pH
as the pH moved towards baseline versus a linear decrease in
gastric pH. These fluctuations could further explain the pow-
erful buffering effect of food at attempting to maintain elevat-
ed gastric pH and the insignificant differences in AUCpH.
When looking at comparison 2, there was a statistically
significant difference between the 4500 mg BHCl arm and
both the control, the 1500 mg arm and the 3000 mg arm.
The 1500 mg and the 3000 mg doses did not provide a faster
time to baseline when compared to the control arm
(Table III), and the time to baseline for these two arms were
Table II Time From Food Administration to Baseline pH
Comparison 1 Difference of Means (time to baseline in mins) GMR 90% CI of Difference in Means t P Value Significant
Control vs. 4500 mg 32.3 0.34 20.5 to 44.2 8.15 <0.001 Yes
Control vs. 1500 mg 21.9 0.58 7.04 to 36.7 5.52 <0.001 Yes
Control vs. 3000 mg 20.1 0.61 7.72 to 32.5 5.07 <0.001 Yes
3000 mg vs. 4500 mg 12.2 0.56 6.53 to 17.9 3.08 0.001 Yes
1500 mg vs. 4500 mg 10.4 0.59 3.68 to 17.2 2.63 0.013 Yes
3000 mg vs. 1500 mg 1.80 1.05 −7.20 to 3.64 0.45 0.810 No
Table III Time from BHCL to Baseline pH
Comparison 2 Difference of Means (time to baseline in mins) GMR 90% CI of Difference in Means t P Value Significant
Control vs. 4500 mg 17.3 0.51 5.50 to 29.2 4.34 0.017 Yes
Control vs. 1500 mg 6.90 0.87 −7.96 to 21.7 1.74 0.611 No
Control vs. 3000 mg 5.11 0.91 −7.28 to 17.5 1.29 0.689 No
3000 mg vs. 4500 mg 12.2 0.57 6.53 to 17.9 3.08 0.001 Yes
1500 mg vs. 4500 mg 10.4 0.59 3.68 to 17.2 2.63 0.013 Yes
3000 mg vs. 1500 mg 1.80 1.05 −7.20 to 3.64 0.45 0.810 No
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similar to one another. As mentioned previously, these doses
were not high enough to counteract the strong gastric pH
effect of food.
The potential for drug interactions resulting from PPI’s
prescribed for digestive disorders is clear, however, the con-
comitant use of ARAs is also abundant in the setting of other
clinical diseases. Two clinical areas very well studied include
HIV and oncology, where studies have shown reduced sys-
temic exposure to the therapeutic drug with concomitant
ARA dosing (11,16–19). Approximately 33% of patients re-
ceiving an anticancer agent are also simultaneously prescribed
an ARA (11), and many of these cancer agents have product
labels (e.g. erlotinib) stating that ARAs should not be taken
concomitantly (19). These pH interactions depend on the type
of ARA used, the dose of ARA and the time of ARA admin-
istration relative to the pH dependent drug. Of the ARAs, the
PPIs are the most potent as they are responsible for reducing
acid in the stomach by irreversibly binding to the gastric pro-
ton pump (H+/K+ ATPase) at the secretory surface of parietal
cells (20). PPIs drastically elevate gastric pH and thus cause the
greatest concern for drug-drug interactions. A primary exam-
ple of a compound that highlights these interactions is
atazanavir (ATV), a weakly basic protease inhibitor with a
pKa = 4.25 (21). In a study by Zhu et al. (22), low dose omep-
razole (20 mg) was co-administered to 56 healthy volunteers
given ATV/RTV once daily. The resulting ATV area under
the curve (AUC0–24) and trough concentrations (Cmin), in the
presence of low dose omeprazole (20 mg), were reduced by
42% (90% CI of geometric mean ratio: 0.44–0.75) and 46%
(90% CI of geometric mean ratio: 0.41–0.71), respectively
(22). The decrease in AUC0–24 and Cmin are significant.
This pharmacokinetic interaction was also found to be dose-
dependent as a previous study looking at the impact of
omeprazole 40 mg on ATV bioavailability demonstrated a
decrease of about 75% (22).
Another important factor to consider when discussing drug
absorption is the effect of food on the physiology of the gas-
trointestinal tract, including gastric pH and its ability to affect
the bioavailability of drugs. The ability of food to raise gastric
pH levels has been well studied and documented (23–25).
Furthermore, food impacts bioavailability through a number
of variables, such as delayed gastric emptying, direct dissolu-
tion and absorption effects, physically or chemically
interacting with drug molecules, biotransformation, stimula-
tion of bile flow, and increased splanchnic blood flow.
Furthermore the food content, the timing of food versus drug
administration, and the biopharmaceutics classification sys-
tem (BCS) class of the drug are also vital considerations
(3,24,26). Despite the ample amount of research regarding
the effect of food on drug bioavailability, a mechanistic pre-
diction of the impact of food on specific chemical entities or a
class of drugs has not been fully established (24).
Food serves as a buffer and elevates gastric pH like ARA’s
do albeit in a different way, thus having similarly profound
effects on pharmacokinetic parameters for weakly basic drugs
that exhibit pH-dependent solubility (3,6). Molecules that
have pH dependent solubility must be ionized to be soluble,
however, absorption via diffusion through the lipid bilayer will
be enhanced for unionized compounds. Weakly basic drugs,
especially poorly water soluble and highly permeable drugs (3)
(BCS class II) will dissolve more readily in the acidic environ-
ment of the stomach as they will be ionized. However, as
gastric pH levels rise after a meal or the administration of
ARAs, weakly basic drugs become unionized and precipitate
due to a reduction in their solubility. The percent of ionization
for weakly basic drugs is therefore vulnerable to the pH in its
environment. The Henderson-Hasselbalch equation demon-
strates the importance of having amolecule in a pH range that
will allow it to be ionized for solubility and unionized for
absorption. For example, a weakly basic drug (BCS class II),
such as ATV with a pKa of 4.2, will be 50% ionized and 50%
unionized when the pH= pKa. In order for a weakly basic
drug to be ionized and solubilized, we want the pH< pKa to
ensure a high proportion of ionized to unionized drug. In
contrast, absorption from the small intestine will be facilitated
by the unionized state. This occurs when the pH is greater
than the pKa of the drug. A majority of drug absorption oc-
curs in the upper portion of the small intestine (jejunum and
duodenum) (3).
Given the complexity of drug solubility and the number of
variables that contribute to drug bioavailability, it is impera-
tive to develop and discuss methods to alleviate these pH-
based interactions. In 1994, Chin et al. demonstrated the abil-
ity of an acidic beverage such as Coca-Cola (pH of 2.5) to
improve the absorption of ketoconazole in the presence of
omeprazole induced achlorhydria (4). The area under the
Table IV Mean Max pH
N=9 Mean Max pH STDV Mean Max pH (all arms) p value
Food only 3.02 0.62 3.2 p=0.670
1500 mg 3.30 0.49
3000 mg 3.17 0.52
4500 mg 3.30 0.45
Table V AUCpH (From Food Administration)
N=9 Mean AUCpH STDV p value
Food only 68.1 34.4 p=0.990
1500 mg 67.0 17.8
3000 mg 70.1 17.0
4500 mg 69.7 27.0
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curve (AUC0-∞) and the maximum plasma concentration
(Cmax) were increased by more than 10-fold with treatment
of Coca-Cola in comparison to ketoconazole alone (4).
Another example utilizing Coca-Cola as a reacidfying agent
involved posaconazole. In this study, Coca-Cola was success-
ful in regaining lost bioavailability due to drug-induced
achlorhydria (27). Another study utilizing Coca-Cola and
ATV in healthy subjects pretreated with omeprazole was not
able to demonstrate any considerable recovery of bioavailabil-
ity (28). Of these three studies, the ketoconazole and
posaconazole examples demonstrate the potential viability of
reacidification strategies and the necessity for research.
We have demonstrated the importance of increasing doses
of BHCl, specifically that the highest dose of BHCl (4500 mg)
is the most potent in terms of time to re-acidify gastric pH to
baseline levels in the presence of food. The probable explana-
tion for the inability for Faber et al. to replicate previous studies
fromYago et al.was due to the powerful food effect on increas-
ing and maintaining elevated gastric pH even in the presence
of 1500 mg BHCl. Previous studies did not include food, and
as a result, managing the impact of food on gastric pH is
complex. The effect of food is often regarded as a minor factor
that can be manipulated by adjusting dose administration of
various drugs in relation to the food. However, as we have
demonstrated, the gastric food effect on pH is much more
powerful than anticipated. This study has served as a means
of elucidating the gastric pH effect and suggests that the ele-
vation in gastric pH seen with food is much different than
ARA-induced hypochlorhydria.
This study reflects the conundrum faced by clinicians in
administering weakly basic drugs in patients receiving ARAs.
Clinically, it is recommended to dose atazanavir with food to
minimize GI irritation from the drug formulation. But the
concomitant meal will markedly increase gastric pH, resulting
in poor bioavailability due to solubility issues that can lead to a
higher chance of treatment failure and drug resistance. The
clinician can recommend that patients wait about 50 min
when food pH effects are diminished. But we do not know if
this would still provide the positive effects of the meal on
reducing gastric irritation. Alternatively, we show here that a
large BHCl dose (4500 mg) will yield a rapid (~17 min) de-
crease in stomach pH that will allow solubilization, as we
demonstrated earlier in fasted subjects receiving ARAs with
a 1500 mg BHCl dose.
Although the most potent dose of BHCl, in terms of fastest
time to baseline was the 4500 mg dose, the AUCpH values did
not inversely decrease as the dose of BHCl was increased. We
expected that as the dose of BHCl was increased, we would
see a faster time to baseline pH and as a result, the area under
the time vs. pH curve would be the smallest. The data showed
no significant differences among the different groups. One
postulate as to why the AUCpH did not decrease with the
increasing doses of the BHCl acid is because of the
fluctuations in pH after the administration of the acid, further
demonstrating the gastric pH effect of the food and its ability
to maintain elevated pH levels. The decline of the slope on the
pH vs. time curve was non-linear, with fluctuations in the pH
that contributed to the AUCpH.
Limitations
The standardized meal we chose to administer was based on
the Institute of Medicine’s recommendation for caloric break-
down of fat, protein and carbohydrates. This is not necessarily
a standard diet for many individuals in the USA. Since the
impact of food on gastric pH is quite complex, different types
of food could potentially alter the gastric pH response and
thereby alter drug availability.
Another limitation was the Heidelberg device. We dealt
with a range of technical issues ranging from interference in
the transmission of pH data from the capsule to the computer
to devices sending erroneously inaccurate values to the pH
laptop. This resulted in a lot of data clean up that was required
in order to ensure consistency. We worked with Heidelberg to
help overcome the technical problems.
The sample size of N= 9 was thought to be adequately
powered based on previous studies, however, a larger sample
size may have helped to tease out the between-treatment ef-
fects of the various BHCl doses. Moreover, the FDA does not
regulate the standards of nutraceutical medicines as strictly as
pharmaceutical drugs. The BHCl used was from a facility
compliant with the FDA’s Good Manufacturing Process
(GMP) requirements. Quantitative mass spectrometry was
not performed to ensure the dosing of the BHCl nutraceutical
capsules to ensure the accuracy of the dosing.
In addition to the above-mentioned limitations, we also
dealt with some patient difficulty in swallowing the BHCl
capsules. These capsules came in only 750 mg doses. When
subjects were taking 4500 mg, they were required to swallow
six of these capsules, which are larger than standard vitamin
pills. This could have been one source of the fluctuation we
observed in the pH vs. time graphs due to the various capsules
opening and releasing its acidic content at various times in the
gastric environment. Additionally, these fluctuations may
have been enhanced by food-induced increase in gastric fluid
viscosity, resulting in less BHCl disintegration and dissolution.
Lastly, the variability of water administered in the different
periods could potentially lead to inconsistency in the gastric
pH readings. Subjects who were unable to swallow all six
BHCl capsules were given up to an additional 250 ml if de-
sired. Additionally, in the food only arm subjects were able to
drink up to 250 ml of water during the administration of food.
The water administered during food was unlikely to affect the
accuracy of BHCl to re-acidify gastric pH given both water
and food serve as a buffer. It is unlikely that such a dosing
paradigm could be used in patients.
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CONCLUSION
Overall, this study has provided valuable data and insight
concerning the environment of gastric reacidification strategies
in the presence of food. Previous data by Yago et al. has sug-
gested the impactful and translational role that orally admin-
istered BHCl could have on solubility and absorption of weak-
ly bas ic drugs in the presence of drug- induced
hypochlorhydria. The process is complicated with multiple
factors, including BHCl disintegration and dissolution relative
to gastric emptying, and a potential increase in gastric viscosity
and BHCl. We sought to determine the effect of food on gas-
tric pH as well as the impact of increasing doses of BHCl on
gastric pH reacidification in the presence of food. The clinical
relevance of these data suggest that when giving patients weak-
ly basic medications that require low gastric pH for solubility
and proper absorption, themedicationmust be given about an
hour after the administration of food or approximately 20min
if using 4500 mg of BHCl. The gastric pH effect of food is best
overcome with the 4500 mg dose of BHCl, but this is likely an
unacceptably large dose for continuous administration using
the given the available dosage forms discussed. More concen-
trated capsules or powder formulations of BHCl would be a
more feasible option in a clinical setting.
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